4006 Background: ECF (epirubicin, cisplatin, fluorouracil), IC (irinotecan, cisplatin), and
FOLFOX (leucovorin, fluorouracil, oxaliplatin) are commonly used regimens for …

Purpose To determine the optimal chemotherapy backbone for testing in future US
cooperative group studies for metastatic esophageal and gastroesophageal junction …

Introduction On the basis of the promising activity of cetuximab and radiation therapy for
head and neck cancers, we evaluated the efficacy of this regimen followed by surgery in …

Background This study assessed the activity of the mAb cetuximab in combination with
cisplatin and 5-fluorouracil (5-FU) in advanced esophageal squamous cell carcinoma …

4536 Background: Survival for patients (pts) with metastatic esophageal cancer is poor, with
no established therapy for patients failing first-line treatment. Esophageal adenocarcinoma …

4031 Background: Aim of this study was to evaluate efficacy and safety of cetuximab plus
FOLFIRI as first-line treatment for advanced gastric or GEJ cancer. Methods: Eligibility …

Background: The purpose of this phase II study was to evaluate the efficacy and safety of
cetuximab combined with FOLFIRI as a first-line treatment of advanced gastric or …

Introduction: The specific aims of the study were to evaluate the 2-year overall survival (OS)
and progression-free survival (PFS), toxicity profile, and best objective response rate in …

Introduction Esophageal adenocarcinomas commonly express the epidermal growth factor
receptor. This trial assessed the 6-month overall survival probability in metastatic …

4054 Background: Conventional chemotherapeutic agents are of limited benefit in patients
(pts) with recurrent or metastatic cancer of the esophagus or GEJ. We report preliminary …